NEW YORK (GenomeWeb News) – Shares in Illumina were down 12.19 percent, or 3.36, at $31.40 in mid-afternoon trading after the company disclosed changes to the severance packages of six company officials.
Separately today, investment bank Leerink Swann downgraded the company's stock to "Market Perform" from "Outperform."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.